Key Takeaways From Emergent BioSolutions Analyst Ratings

During the last three months, 4 analysts shared their evaluations of Emergent BioSolutions EBS, revealing diverse outlooks from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for Emergent BioSolutions, revealing an average target of $7.25, a high estimate of $8.00, and a low estimate of $5.00. Marking an increase of 3.57%, the current average surpasses the previous average price target of $7.00.

Exploring Analyst Ratings: An In-Depth Overview

The standing of Emergent BioSolutions among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Emergent BioSolutions. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Emergent BioSolutions compared to the broader market.
• Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Emergent BioSolutions's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Emergent BioSolutions analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

About Emergent BioSolutions

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions: A Financial Overview

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Revenue Growth: Emergent BioSolutions's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 85.3%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.08%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Emergent BioSolutions's ROE excels beyond industry benchmarks, reaching 1.37%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Emergent BioSolutions's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.5% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Emergent BioSolutions's debt-to-equity ratio surpasses industry norms, standing at 1.36. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

Understanding the Relevance of Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.